니볼루맙 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 CAGR 13.4%로 32억 달러로 성장할 것으로 예측됩니다. 예측 기간 중의 성장은 맞춤의료, 새로운 적응증, 세계 암 치료 접근성, 병용요법의 발전에 기인하는 것으로 보입니다. 예측 기간 중 주요 동향으로는 바이오마커 기반 치료, 새로운 항원 백신, 면역요법 요법 강화, 장기 추적 조사 등이 있습니다.
암 유병률 증가는 향후 니볼루맙 시장의 성장을 촉진할 것으로 예상됩니다. 암은 비정상적인 세포가 통제할 수 없을 정도로 증식하여 정상 경계를 뚫고 다른 장기로 전이되거나 주변 조직으로 침범하여 신체의 거의 모든 장기와 조직에 발생할 수 있는 질병군입니다. 니볼루맙은 암세포가 면역체계를 억제하는 것을 막고, 면역체계가 암세포를 공격하고 파괴할 수 있도록 하여 다양한 유형의 암을 치료하는 데 사용됩니다. 예를 들어 2024년 7월 호주 정부 기관인 호주보건복지연구소(Australian Institute of Health and Welfare)는 호주에서 진단된 암 환자 수가 2021년 15만 6,781건에서 2022년에는 16만 570건으로 증가하여 1년 만에 3,789건 증가했다고 보고했습니다. 결과적으로 암 유병률 증가는 니볼루맙 시장의 성장을 촉진하고 있습니다.
비소세포폐암(NSCLC)의 발병률 증가는 당분간 니볼루맙 시장 성장의 두드러진 촉진제가 될 것으로 예상되며, NSCLC는 폐의 상피세포에서 발생하는 폐암의 일종으로 니볼루맙의 주요 표적 영역입니다. 니볼루맙은 진행성 비소세포폐암(NSCLC) 치료제로 승인되어 그 효능이 입증된 바 있습니다. 미국임상종양학회 자료에 따르면 2023년 3월 미국에서 폐암 진단을 받을 환자는 23만 8,340명(남성 11만 7,550명, 여성 12만 790명)으로 추산됩니다. 이 중 비소세포폐암이 우세한 아형으로 전체 폐암 진단의 약 81%를 차지합니다. 따라서 비소세포폐암(NSCLC) 발병률 증가는 니볼루맙 시장의 강력한 성장 동력이 되고 있습니다.
세계의 니볼루맙 시장에 대해 조사했으며, 시장의 개요와 유형별, 투여 경로별, 용도별, 최종사용자별, 유형별, 지역·국가별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
목차
제1장 개요
제2장 니볼루맙 시장의 특징
제3장 니볼루맙 시장 동향과 전략
제4장 니볼루맙 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 니볼루맙 성장 분석과 전략 분석 프레임워크
- 세계 니볼루맙 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인, 억제요인)
- 최종 용도 산업의 분석
- 세계의 니볼루맙 시장의 성장률 분석
- 세계의 니볼루맙 시장 규모 실적과 성장, 2019-2024년
- 세계의 니볼루맙 시장 규모와 성장 예측, 2024-2029년, 2034년 예상
- 세계의 니볼루맙 TAM(Total Addressable Market)
제6장 니볼루맙 시장 세분화
- 세계의 니볼루맙 시장, 유형별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
- 주사액 4mL
- 주사액 10mL
- 세계의 니볼루맙 시장, 투여 경로별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
- 정맥내
- 기타
- 세계의 니볼루맙 시장, 용도별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
- 악성 흑색종
- 비소세포 폐암(NSCLC)
- 악성 흉막중피종
- 고전적 호지킨 림프종(CHL)
- 두경부 편평 상피암(SCCHN)
- 신세포암(RCC)
- 기타
- 세계의 니볼루맙 시장, 최종사용자별 세분화, 실적 및 예측, 2019-2024년, 2024-2029년, 2034년
- 클리닉
- 병원
- 기타
- 세계의 니볼루맙 시장, 주사제 4mL의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
- 싱글 도스 바이알
- 멀티 도스 바이알
- 세계의 니볼루맙 시장, 주사제 10mL의 서브 세분화, 유형별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
- 싱글 도스 바이알
- 멀티 도스 바이알
제7장 니볼루맙 시장의 지역별 및 국가별 분석
- 세계의 니볼루맙 시장, 지역별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
- 세계의 니볼루맙 시장, 국가별, 실적 및 예측, 2019-2024년, 2024-2029년 예측, 2034년 예측
제8장 아시아태평양의 니볼루맙 시장
제9장 중국의 니볼루맙 시장
제10장 인도의 니볼루맙 시장
제11장 일본의 니볼루맙 시장
제12장 호주의 니볼루맙 시장
제13장 인도네시아의 니볼루맙 시장
제14장 한국의 니볼루맙 시장
제15장 서유럽의 니볼루맙 시장
제16장 영국의 니볼루맙 시장
제17장 독일의 니볼루맙 시장
제18장 프랑스의 니볼루맙 시장
제19장 이탈리아의 니볼루맙 시장
제20장 스페인의 니볼루맙 시장
제21장 동유럽의 니볼루맙 시장
제22장 러시아의 니볼루맙 시장
제23장 북미의 니볼루맙 시장
제24장 미국의 니볼루맙 시장
제25장 캐나다의 니볼루맙 시장
제26장 남미의 니볼루맙 시장
제27장 브라질의 니볼루맙 시장
제28장 중동의 니볼루맙 시장
제29장 아프리카의 니볼루맙 시장
제30장 니볼루맙 시장의 경쟁 구도와 기업 개요
- 니볼루맙 시장의 경쟁 구도
- 니볼루맙 시장 기업 개요
- Pfizer Inc.
- Johnson &Johnson Services Inc.
- F. Hoffmann-La Roche Ltd.
- Merck &Co. Inc.
- AbbVie Inc.
제31장 니볼루맙 시장 기타 대형 및 혁신적 기업
- Novartis AG
- Sanofi S.A.
- Bristol-Myers Squibb Company
- AstraZeneca plc
- GlaxoSmithKline plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Amgen Inc.
- Regeneron Pharmaceuticals Inc.
- Astellas Pharma Inc.
- Chugai Pharmaceutical Co. Ltd.
- Daiichi Sankyo Company Limited
- Eisai Co. Ltd.
- Ono Pharmaceutical Co. Ltd.
- Kyowa Kirin Co. Ltd.
제32장 세계의 니볼루맙 시장의 경쟁 벤치마킹과 대시보드
제33장 니볼루맙 시장에서의 주요 합병과 인수
제34장 니볼루맙 시장의 최근 동향
제35장 니볼루맙 시장의 잠재적 가능성이 높은 국가, 부문, 전략
- 2029년 니볼루맙 시장 - 가장 새로운 기회를 제공하는 국가
- 2029년 니볼루맙 시장 - 가장 새로운 기회를 제공하는 부문
- 2029년 니볼루맙 시장 - 성장 전략
제36장 부록
KSA
Nivolumab is an immunoglobulin G4 (IgG4) fully human antibody that targets programmed cell death protein 1 (PD1). It is approved at a dosage of 3 mg/kg for the treatment of metastatic or unresectable melanoma, metastatic non-small cell lung cancer following platinum-based chemotherapy, and metastatic renal cell carcinoma in the second-line setting. Nivolumab is a targeted therapy medication employed in the management and treatment of various types of cancer, and it operates by enhancing the immune system's response to cancer cells.
Nivolumab is available in two main formulations such as an injection of 4 mL and an injection of 10 mL. The 40 mg/4 mL (10 mg/mL) solution of nivolumab is provided in single-use vials. This formulation is utilized in the treatment of melanoma, non-small cell lung cancer (NSCLC), and Hodgkin lymphoma. It is administered via intravenous and other routes for the treatment of conditions such as melanoma, NSCLC, malignant pleural mesothelioma, classical Hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and other cancer types. Nivolumab is used in clinical settings, hospitals, and other healthcare facilities for cancer treatment.
The nivolumab market research report is one of a series of new reports from The Business Research Company that provides nivolumab market statistics, including nivolumab industry global market size, regional shares, competitors with a nivolumab market share, detailed nivolumab market segments, market trends and opportunities and any further data you may need to thrive in the nivolumab industry. This nivolumab market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The nivolumab market size has grown rapidly in recent years. It will grow from $1.69 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to immunotherapy advancements, increased incidence of cancer, clinical trial success, regulatory approvals.
The nivolumab market size is expected to see rapid growth in the next few years. It will grow to $3.2 billion in 2029 at a compound annual growth rate (CAGR) of 13.4%. The growth in the forecast period can be attributed to personalized medicine, emerging indications, global access to cancer care, advancements in combination therapies. Major trends in the forecast period include biomarker-driven treatment, neoantigen vaccines, enhanced immunotherapy regimens, long-term follow-up studies.
The increasing prevalence of cancer is expected to drive the growth of the nivolumab market in the future. Cancer is a group of diseases that can occur in nearly any organ or tissue in the body when abnormal cells grow uncontrollably, break through normal boundaries, and either spread to other organs or invade surrounding tissues. Nivolumab is used to treat various types of cancer by preventing cancer cells from suppressing the immune system, allowing the immune system to attack and destroy the cancer cells. For example, in July 2024, the Australian Institute of Health and Welfare, an Australian government agency focused on providing health and welfare data and analysis, reported that the number of cancer cases diagnosed in Australia increased from 156,781 in 2021 to 160,570 in 2022, marking an increase of 3,789 cases over the one-year period. As a result, the rising prevalence of cancer is fueling the growth of the nivolumab market.
The increasing incidence of non-small cell lung cancer (NSCLC) is poised to be a prominent driver for the Nivolumab market's growth in the foreseeable future. NSCLC, a prevalent form of lung cancer originating in the epithelial cells of the lungs, is a major area of focus for Nivolumab. The drug has garnered approval for the treatment of advanced non-small cell lung cancer (NSCLC) owing to its proven efficacy in addressing this specific condition. Notably, data from the American Society of Clinical Oncology reveals that an estimated 238,340 individuals (comprising 117,550 men and 120,790 women) are anticipated to receive a lung cancer diagnosis in the United States in March 2023. Among these cases, NSCLC is the predominant subtype, representing approximately 81% of all lung cancer diagnoses. Consequently, the increased incidence of non-small cell lung cancer (NSCLC) stands as a formidable growth driver for the Nivolumab market.
Prominent companies operating within the Nivolumab market are placing a significant emphasis on the development of innovative drugs aimed at enhancing patient care and sustaining their market positions. The creation of novel drugs holds the potential to improve treatment outcomes for patients grappling with various medical conditions. As an illustration, in May 2022, Bristol-Myers Squibb Co., a US-based pharmaceutical company primarily dedicated to therapeutic endeavors encompassing cancer, cardiovascular health, immunology, and fibrotic conditions, disclosed the FDA's approval of two Nivolumab-based regimens. These regimens included Nivolumab in combination with fluoropyrimidine and platinum-containing chemotherapy and Nivolumab paired with Yervoy (ipilimumab), for the first-line treatment of adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.
In November 2022, Lyvgen Biopharma Co. Ltd., a China-based biotechnology firm specializing in cancer treatment, entered into a collaborative partnership with Bristol-Myers Squibb Co. The collaboration's focal point is the assessment of LVGN7409 in conjunction with Nivolumab, targeting patients with non-small cell lung cancer. This combination therapy concurrently addresses the co-stimulatory checkpoint CD40 and the co-inhibitory checkpoint PD-1. This multifaceted approach is envisioned to enhance the effectiveness of immunotherapy for patients confronting diseases that exhibit resistance or refractoriness. Bristol-Myers Squibb Co. is a US-based pharmaceutical company with a primary focus on therapeutic domains spanning cancer, cardiovascular health, immunology, and fibrotic disorders, inclusive of pioneering developments in Nivolumab.
Major companies operating in the nivolumab market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Nippon Kayaku Co. Ltd., Luye Pharma AG, Genentech Inc., Taiho Pharmaceutical Co. Ltd., SymBio Pharmaceuticals Ltd., Xbrane Biopharma AB, NeuClone Therapeutics Inc.
North America was the largest region in the nivolumab market in 2024. The regions covered in nivolumab report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the nivolumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The nivolumab market consists of sales of opdivo, nivolumab injection, generic Nivolumab. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Nivolumab Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on nivolumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for nivolumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nivolumab market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Type: Injection 4mL; Injection 10mL
- 2) By Route Of Administration: Intravenous; Other Routes Of Administration
- 3) By Application: Melanoma; Non-small Cell Lung Cancer (NSCLC); Malignant Pleural Mesothelioma; Classical Hodgkin Lymphoma (CHL); Squamous Cell Carcinoma Of The Head And Neck (SCCHN); Renal Cell Carcinoma (RCC); Other Applications
- 4) By End-User: Clinic; Hospital; Other End-Users
- Subsegments:
- 1) By Injection 4mL: Single-Dose Vial; Multi-Dose Vial
- 2) By Injection 10mL: Single-Dose Vial; Multi-Dose Vial
- Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Nivolumab Market Characteristics
3. Nivolumab Market Trends And Strategies
4. Nivolumab Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Nivolumab Growth Analysis And Strategic Analysis Framework
- 5.1. Global Nivolumab PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Nivolumab Market Growth Rate Analysis
- 5.4. Global Nivolumab Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Nivolumab Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Nivolumab Total Addressable Market (TAM)
6. Nivolumab Market Segmentation
- 6.1. Global Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injection 4mL
- Injection 10mL
- 6.2. Global Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Intravenous
- Other Routes Of Administration
- 6.3. Global Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Malignant Pleural Mesothelioma
- Classical Hodgkin Lymphoma (CHL)
- Squamous Cell Carcinoma Of The Head And Neck (SCCHN)
- Renal Cell Carcinoma (RCC)
- Other Applications
- 6.4. Global Nivolumab Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Clinic
- Hospital
- Other End-Users
- 6.5. Global Nivolumab Market, Sub-Segmentation Of Injection 4mL, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single-Dose Vial
- Multi-Dose Vial
- 6.6. Global Nivolumab Market, Sub-Segmentation Of Injection 10mL, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Single-Dose Vial
- Multi-Dose Vial
7. Nivolumab Market Regional And Country Analysis
- 7.1. Global Nivolumab Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Nivolumab Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Nivolumab Market
- 8.1. Asia-Pacific Nivolumab Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Nivolumab Market
- 9.1. China Nivolumab Market Overview
- 9.2. China Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Nivolumab Market
- 10.1. India Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Nivolumab Market
- 11.1. Japan Nivolumab Market Overview
- 11.2. Japan Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Nivolumab Market
- 12.1. Australia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Nivolumab Market
- 13.1. Indonesia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Nivolumab Market
- 14.1. South Korea Nivolumab Market Overview
- 14.2. South Korea Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Nivolumab Market
- 15.1. Western Europe Nivolumab Market Overview
- 15.2. Western Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Nivolumab Market
- 16.1. UK Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Nivolumab Market
- 17.1. Germany Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Nivolumab Market
- 18.1. France Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Nivolumab Market
- 19.1. Italy Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Nivolumab Market
- 20.1. Spain Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Nivolumab Market
- 21.1. Eastern Europe Nivolumab Market Overview
- 21.2. Eastern Europe Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Nivolumab Market
- 22.1. Russia Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Nivolumab Market
- 23.1. North America Nivolumab Market Overview
- 23.2. North America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Nivolumab Market
- 24.1. USA Nivolumab Market Overview
- 24.2. USA Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Nivolumab Market
- 25.1. Canada Nivolumab Market Overview
- 25.2. Canada Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Nivolumab Market
- 26.1. South America Nivolumab Market Overview
- 26.2. South America Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Nivolumab Market
- 27.1. Brazil Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Nivolumab Market
- 28.1. Middle East Nivolumab Market Overview
- 28.2. Middle East Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Nivolumab Market
- 29.1. Africa Nivolumab Market Overview
- 29.2. Africa Nivolumab Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Nivolumab Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Nivolumab Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Nivolumab Market Competitive Landscape And Company Profiles
- 30.1. Nivolumab Market Competitive Landscape
- 30.2. Nivolumab Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Nivolumab Market Other Major And Innovative Companies
- 31.1. Novartis AG
- 31.2. Sanofi S.A.
- 31.3. Bristol-Myers Squibb Company
- 31.4. AstraZeneca plc
- 31.5. GlaxoSmithKline plc
- 31.6. Takeda Pharmaceutical Company Limited
- 31.7. Eli Lilly and Company
- 31.8. Amgen Inc.
- 31.9. Regeneron Pharmaceuticals Inc.
- 31.10. Astellas Pharma Inc.
- 31.11. Chugai Pharmaceutical Co. Ltd.
- 31.12. Daiichi Sankyo Company Limited
- 31.13. Eisai Co. Ltd.
- 31.14. Ono Pharmaceutical Co. Ltd.
- 31.15. Kyowa Kirin Co. Ltd.
32. Global Nivolumab Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Nivolumab Market
34. Recent Developments In The Nivolumab Market
35. Nivolumab Market High Potential Countries, Segments and Strategies
- 35.1 Nivolumab Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Nivolumab Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Nivolumab Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
